Scilex (NASDAQ:SCLX) Announces Earnings Results

Key Points

• Scilex reported quarterly EPS of ($4.60), missing the consensus estimate of ($0.47) by ($4.13), signaling a much larger-than-expected loss for the period.
• The stock opened at $6.80 with a market capitalization of $57.73 million, a negative PE of -0.21, and a 52-week range of $3.60 to $34.27, reflecting substantial volatility and a steep decline from prior highs.
• Institutional activity has increased—Armistice Capital boosted its stake by 622.2% and overall institutional ownership is ~69.7%—yet analysts remain cautious, with Weiss Ratings reaffirming a "Sell" and the consensus analyst rating listed as Sell.

Scilex (NASDAQ:SCLX - Get Free Report) released its quarterly earnings results on Friday. The company reported ($4.60) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($4.13), Zacks reports.

Scilex Stock Performance

SCLX opened at $6.80 on Friday. The business's 50-day simple moving average is $7.93 and its 200 day simple moving average is $13.37. Scilex has a 52-week low of $3.60 and a 52-week high of $34.27. The firm has a market capitalization of $57.73 million, a PE ratio of -0.21 and a beta of 1.40.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC raised its stake in shares of Scilex by 622.2% during the 4th quarter. Armistice Capital LLC now owns 476,674 shares of the company's stock worth $5,815,000 after purchasing an additional 410,674 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Scilex by 31.2% in the first quarter. Goldman Sachs Group Inc. now owns 136,352 shares of the company's stock valued at $34,000 after buying an additional 32,449 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Scilex by 100.7% during the fourth quarter. Renaissance Technologies LLC now owns 38,464 shares of the company's stock worth $469,000 after buying an additional 19,300 shares during the last quarter. 683 Capital Management LLC acquired a new position in Scilex during the fourth quarter worth $333,000. Finally, XTX Topco Ltd bought a new stake in Scilex during the fourth quarter worth $249,000. Institutional investors and hedge funds own 69.67% of the company's stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Scilex in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of "Sell".

Scilex Company Profile

Scilex Holdings, Inc NASDAQ: SCLX is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm's principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.